CADL (Candel Therapeutics) Interest Expense: $-3.38 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CADL Candel Therapeutics Inc CADL
30 GF Score
Price $10.17
! 3 Warning Signs
View Full Analysis

What is Candel Therapeutics Interest Expense?

Candel Therapeutics CADL +7.38% 30 Interest Expense is $-3.38 Mil as of Mar. 2026. GuruFocus rates CADL with a GF Score™ of 30/100. The stock has 3 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Candel Therapeutics's interest expense for the three months ended in Mar. 2026 was $ -1.56 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was $-3.38 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Candel Therapeutics's Operating Income for the three months ended in Mar. 2026 was $ -16.26 Mil. Candel Therapeutics's Interest Expense for the three months ended in Mar. 2026 was $ -1.56 Mil. Candel Therapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Candel Therapeutics  (NAS:CADL) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Candel Therapeutics's Interest Expense for the three months ended in Mar. 2026 was $-1.56 Mil. Its Operating Income for the three months ended in Mar. 2026 was $-16.26 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was $48.82 Mil.

Candel Therapeutics's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Candel Therapeutics did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Candel Therapeutics Interest Expense Historical Data

* Premium members only.

The historical data trend for Candel Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Candel Therapeutics Interest Expense Chart

Candel Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial -0.05 -1.71 -2.60 -2.09 -2.12

Candel Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.31 -0.24 -0.16 -1.42 -1.56
CADL
30GF Score
Candel Therapeutics Inc CADL
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Candel Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.38 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of $-3.38 Mil mean?
Candel Therapeutics (CADL) has a Interest Expense of $-3.38 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Candel Therapeutics and its competitors.
Is Candel Therapeutics' Interest Expense too high?
Candel Therapeutics' current Interest Expense is $-3.38 Mil. Overall, Candel Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Candel Therapeutics' Interest Expense compare to AURA and RIGL?
Candel Therapeutics' Interest Expense of $-3.38 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Candel Therapeutics and its competitors. Candel Therapeutics's current Interest Expense is $-3.38 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Candel Therapeutics stock overvalued right now?
Candel Therapeutics (CADL) has a current Interest Expense of $-3.38 Mil. The current Interest Expense is $-3.38 Mil. Candel Therapeutics' overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Candel Therapeutics (CADL), the current Interest Expense is $-3.38 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Candel Therapeutics Business Description

Address 117 Kendrick Street, Suite 450, Needham, MA, USA, 02494
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
30GF Score

Get the complete analysis for CADL

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.17
Price